(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 2.88% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Merck & Co's revenue in 2023 is $58,974,000,000.On average, 5 Wall Street analysts forecast MRK's revenue for 2023 to be $147,256,751,478,806, with the lowest MRK revenue forecast at $140,505,103,557,467, and the highest MRK revenue forecast at $151,420,525,800,276. On average, 5 Wall Street analysts forecast MRK's revenue for 2024 to be $154,678,897,542,450, with the lowest MRK revenue forecast at $148,749,146,398,606, and the highest MRK revenue forecast at $162,115,016,173,306.
In 2025, MRK is forecast to generate $163,203,438,846,380 in revenue, with the lowest revenue forecast at $154,499,424,467,638 and the highest revenue forecast at $171,907,453,225,122.